The American pharmaceutical pricing and market access landscape is rapidly evolving. Companies are introducing new products like gene therapies that require alternative pricing models. Payers are seeking to increase their negotiating power through joint healthcare ventures. Regulators are approving products based on real-world evidence. Meanwhile, presidential candidates are offering very different healthcare policy visions with huge implications for drug pricing.
The FT Pharma Pricing and Value Summit will envision the future of market access from different perspectives with a special focus on innovation and collaboration. How can pharma better articulate value to payers and patients? What early steps can be taken to unlock commercial potential in product pipelines? Should the US have an official ICER-like body? You attend - you decide!